Ranbaxy
Laboratories is disappointed with the Decision by the European Commission to
rule its patent settlement agreement with Lundbeck, covering the molecule
Citalopram, anti-competitive, and intends to appeal the Decision to the General
Court of the European Union (EU). These events took place over ten years ago,
and the company considers that the Commission has misunderstood the facts and
misapplied the law. The company believes it has strong grounds of appeal.
Get Free MCX Tips, Stock Tips, Forex Tips & NCDEX Tips,Commodity Tips, Share Tips, commodity tips free trial, nifty free tips, commodity trading tips, shares tips, Share Market Tips, Stock Market Tips, free stock tips on mobile, Stock trading tips, Intraday Tips. or login http://www.epicresearch.co/
No comments:
Post a Comment